Hematologic Cancers News
Ibrutinib + Rituximab Reportedly Superior to Current Standard of Care in Younger Patients With CLL
Three-year outcomes reveal a new standard of care in patients with CLL who are younger than 70.
Rivaroxaban Reduced VTE and VTE-Related Death in Patients With Cancer: Results of the CASSINI Study
Although results indicated rivaroxaban decreased the risk of VTE and VTE-related death in patients with cancer, the benefit was not maintained at study conclusion.
Changes in Microbial Diversity in Patients Undergoing Autologous Hematopoietic Stem Cell Transplant
Loss of intestinal bacterial diversity in patients undergoing AHCT may be comparable to reductions experienced by patients undergoing alloHCT.
CAR-T Cells Successfully Manufactured at Point-of-Care
CAR-T cells targeting CD19 and CD20 were successfully and reproducibly produced at the point-of-care within 14 days.
MCARH171, a BCMA-Targeted CAR-T in Relapsed/Refractory Multiple Myeloma: Phase 1 Readout
A readout of results from a phase 1 trial featuring MCARH171 demonstrates the potential of the human-derived BCMA-targeted CAR-T for R/R MM.
CHIP Associated with Poorer Outcomes in Lymphoma
Clonal hematopoiesis of indeterminate potential is associated with shorter overall and event-free survival after autologous transplant in lymphoma.
Nanjing Legend Biotech Adds More Patient Data for BCMA CAR-T
BCMA expression did not correlate with clinical response.
JCARH125 CAR-T "Highly Active" in Relapsed/Refractory Multiple Myeloma
Patients saw a deepening of responses over time.
Early Findings Indicate P-BCMA-101 May Be Effective, Tolerable in R/R Multiple Myeloma
Early results of phase 1, dose-escalation trial demonstrate efficacy and safety of P-BCMA-101 CAR-T cell therapy in patients with R/R MM.
Further Investigation of AMG 420 in Relapsed/Refractory Multiple Myeloma Warranted
AMG 420 is an anti-B cell maturation antigen bispecific T cell engager antibody construct.
Synchronized Delivery of Proteasome and Bone Marrow Microenvironment Inhibitors in MM
Restricting MM cancer cells from making contact with the bone marrow microenvironment may be achieved through the delivery of inhibitors through nanoparticles.
REGN5458 Demonstrates Antitumor Activity in Myeloma Across Various Preclinical Models
The investigational antibody construct exploits the power of native effector T cells, supporting antitumor activity shortly after administration.
Allogeneic BCMA-Directed CAR-T in Multiple Myeloma: Slated to Hit Phase 1 in 2019
The construct from Allogene has been engineered to avoid the serious immune-related complications linked to allogeneic transplantation.
Front-Line Bendamustine Combination Linked With Stem Cell Mobilization Failure in MCL
Bendamustine-rituximab combination increased risk for day 1 stem cell mobilization failure
Drug Sensitivity Is Genotype-Dependent: Study
Genetically defined mouse models of AEL could help researchers find novel treatment approaches.
New Standard of Care in CLL Proposed for Older Patients
Although PFS with ibrutinib-containing regimens was favorable compared with bendamustine rituximab, overall survival was not different across the study arms.
Luspatercept Reduced RBC Transfusion Dependence in Lower-Risk Patients With Myelodysplastic Syndromes
Findings from the MEDALIST trial revealed a significant reduction in transfusion burden for patients being treated with luspatercept compared with placebo
CAR-T and Ibrutinib: Better Together?
Although CAR-T alone has shown utility in CLL, evidence suggests the addition of ibrutinib could improve the durability of remission.
Liso-Cel Highly Active in Relapsed/Refractory Chronic Lymphocytic Leukemia
Favorable data on liso-cel bolsters its chances of moving into further stages of development, provided complete responses remain durable.
Bendamustine-Rituximab-Bortezomib Promising in R/R Waldenström Macroglobulinemia
High rates of PFS found with salvage treatment with BRB regimen in patients with R/R Waldenstrom macroglobulinemia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Prostate Cancer | Regimens | Drugs |
| Rare Cancers | Regimens | |
| Renal Cell Carcinoma | Regimens | Drugs |
| Skin Cancer | Regimens | Drugs |
| Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Nivolumab Monotherapy Provides Long Term Benefit Advanced Melanoma
- Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer
- Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy
- Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment
- Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer